In order to assess the accuracy of these predictions, a total of 11 thyroid cancer samples with p < 0.01—including the four cases with predicted RET fusions—were subjected to further experimental validation using the targeted NGS panel OncoFu and Sanger sequencing. The gene discussed is RET; the disease is thyroid gland carcinoma.